
Simona Colla

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/757879/publications.pdf Version: 2024-02-01



SIMONA COLLA

#	Article	IF	CITATIONS
1	EZH2 Inhibitors: The Unpacking Revolution. Cancer Research, 2022, 82, 359-361.	0.9	9
2	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine, 2022, 28, 557-567.	30.7	26
3	Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia, 2022, 36, 2097-2107.	7.2	2
4	Telomere dysfunction instigates inflammation in inflammatory bowel disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	28
5	Hematopoiesis under telomere attrition at the single-cell resolution. Nature Communications, 2021, 12, 6850.	12.8	15
6	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Advances, 2019, 3, 922-933.	5.2	84
7	Dysfunctional telomeres and hematological disorders. Differentiation, 2018, 100, 1-11.	1.9	16
8	KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Advances, 2018, 2, 2491-2504.	5.2	29
9	Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncology, The, 2017, 18, 100-111.	10.7	296
10	ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell, 2017, 32, 88-100.e6.	16.8	114
11	RNA processing: a new player of genomic instability in multiple myeloma. Oncoscience, 2017, 4, 73-74.	2.2	3
12	Downregulation of <i>Protection of Telomeres 1</i> expression in myelodysplastic syndromes with 7q deletion. British Journal of Haematology, 2016, 173, 161-165.	2.5	4
13	Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome. Cancer Cell, 2015, 27, 644-657.	16.8	85
14	Passenger deletions generate therapeutic vulnerabilities in cancer. Nature, 2012, 488, 337-342.	27.8	294
15	Telomere dysfunction induces metabolic and mitochondrial compromise. Nature, 2011, 470, 359-365.	27.8	1,093
16	A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 2007, 109, 2276-2284.	1.4	831
17	CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood, 2007, 109, 4995-5001.	1.4	139
18	The molecular classification of multiple myeloma. Blood, 2006, 108, 2020-2028.	1.4	997